ReviewDrugs2014
Current and emerging pharmacotherapeutic options for irritable bowel syndrome.
Review in Drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus.Alimentary pharmacology & therapeutics · 2018Pooled it
- Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement.Scientific reports · 2021Trial
- Gastroparesis in Parkinson's disease: Diagnostic and clinical implications for optimizing pharmacological treatment.Journal of Parkinson's disease · 2026Review
- Determining patient treatment preferences for management of acute pain episodes in irritable bowel syndrome.Neurogastroenterology and motility · 2021Article
- Article
- Chinese Herbal Formula Huoxiang Zhengqi for Dampness Pattern in Atopic Dermatitis and Diarrhea-Predominant Irritable Bowel Syndrome: Rationale and Design of a Master Protocol.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Identification of a Pain-Specific Gene Expression Profile for Pediatric Recurrent Abdominal Pain.Frontiers in pain research (Lausanne, Switzerland) · 2021Article
- Oral Phyto-thymol ameliorates the stress induced IBS symptoms.Scientific reports · 2020Article
- Review
- Acupuncture for irritable bowel syndrome: study protocol for a multicenter randomized controlled trial.Trials · 2018Article
- Article
- Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.British journal of pharmacology · 2017Review
- Rare Variants of the Serotonin Transporter Are Associated With Psychiatric Comorbidity in Irritable Bowel Syndrome.Biological research for nursing · 2016Article
- Towards a systems view of IBS.Nature reviews. Gastroenterology & hepatology · 2015Review
- Eluxadoline: First Global Approval.Drugs · 2015Review
- Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities.Frontiers in psychiatry · 2015Review
- Efficacy of whole system ayurveda protocol in irritable bowel syndrome - A Randomized controlled clinical trial.Journal of Ayurveda and integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of irritable bowel syndrome (IBS) is challenging for both primary care physicians and gastroenterologists because of the heterogeneity of the patient population and the multifactorial pathophysiologies responsible for the symptoms in IBS. This review focuses on the current and emerging pharmacological treatments for IBS. Many of the current medications used to treat this disorder have distinct properties such as efficacy for different symptoms, safety profiles, contraindications, costs, dosing regimens, treatment duration and long-term data. All of these factors, in addition to patient preference and cognitive, food and environmental triggers, must be considered prior to any medication selection. This review will focus on randomized controlled trials with a general uniformity in study design, a rigorous patient selection and appropriate treatment durations. We will also discuss other exciting emerging treatments for IBS such as the µ-opioid receptor (agonists and antagonists), selective κ-opioid receptor agonists, anti-inflammatory drugs, serotonergic agents, bile acid modulators and intestinal bile acid transporters, which may prove promising in treating our patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.